Enabling and leading commercialization and industry partnerships for a healthier world, Commercialization at UHN is the research commercialization hub based at the University Health Network in Toronto. We are the catalyst for accelerating UHN’s world-class research discoveries towards maximum patient impact globally.
Technologies discovered, developed and de-risked at UHN form the basis of products and services improving health care for patients internationally, including therapeutics, devices and diagnostics. In many cases, these represent the foundational platforms for a number of successful companies first incubated within UHN.
The ex-vivo lung perfusion keeps lungs alive outside the body prior to transplant, dramatically increasing the availability of donor lungs and doubling the lung transplant rate—and lives saved—at UHN.Learn More
Precision medicine platform using a single blood test to detect and manage a variety of cancers and other diseasesLearn More
Best-in-class immunotherapies for multiple cancer typesLearn More
Digital health platform supporting patients with heart failure and other chronic conditions.Learn More
Note: Latest fiscal year, unless otherwise stated; all figures in CAD
Commercial success of our most promising innovations and clinical capabilities
And retain world-class commercialization talent at UHN
UHN commercialization expertise has enabled the creation of new companies founded on UHN technologies and collaborations. These companies are now making an impact on health care around the world.
University Health Network has long been a leader in regenerative medicine. In 2016, armed with one of the largest seed investments in biotechnology history, renowned UHN researchers Drs. Gordon Keller and Michael Laflamme, one a world leader in stem cell biology and the other a cardiac cell therapy pioneer, channelled their pioneering stem cell research into the creation of BlueRock Therapeutics, aiming to bring the incredible potential of stem cell therapies from the research lab to the clinic. In 2019, the thriving company was acquired by German pharmaceutical giant Bayer AG for a total company valuation of approximately $1.3 billion – enabling UHN’s stem cell discoveries to translate into commercialized solutions, manufactured at scale for maximum global impact.
Understanding what gives dangerous cancer cells the power to hide and avoid destruction has taken decades of research. Groundbreaking collaborative work between UHN's Princess Margaret Cancer Centre and The Hospital for Sick Children (SickKids) resulted in the discovery of a molecule that can shut down the protective mechanism used by cancer cells to evade destruction. The discovery became a key technology foundational to UHN start-up Trillium Therapeutics, created in the early 2000s. In 2022, decades of this work culminated in Trillium Therapeutics’ acquisition by pharmaceutical giant Pfizer in a US$2.22 billion deal.
Incubated at UHN, Treadwell Therapeutics and subsidiary TCRyption are successfully translating cancer research into groundbreaking immunotherapy treatments for difficult-to-treat cancers. Treadwell is a clinical stage, multi-modality company focused on commercializing oncology research. To date, Treadwell has secured US$91 million in series B financing, built a 9,000-square-foot state-of-the-art lab in Toronto, and established a licensing agreement with UHN to create a pipeline of pre-clinical biologics and small molecule assets. In 2021 Treadwell acquired TCRyption – a UHN incubated biotech company focused on broadening cancer treatment options via T-cell receptor (TCR) technologies developed at the Princess Margaret Cancer Centre.
Drs. Heather Ross and Joseph A. Cafazzo were named 2022 joint Inventors of the Year for revolutionizing cardiac care through Medly, a digital health solution for heart health care from anywhere. Medly reduces heart failure management costs and hospitalizations by 50% and forms the basis of a new UHN venture, Medly Therapeutics, poised to bring heart care benefits to patients around the world.View Past Winners
Proudly sponsored by Commercialization at UHN, the UHN Inventor of the Year Award recognizes an inventor or team who has made a substantial and noteworthy contribution to developing healthcare innovations with high commercialization potential.
Do you think your medical innovation is a contender?